Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

PRINCETON, NJ / ACCESS Newswire / June 6, 2025 /Originally published on University of Kentucky Research News A groundbreaking ...

PRINCETON, NJ / ACCESS Newswire / June 6, 2025 / Originally published on University of Kentucky Research NewsA groundbreaking lung cancer screening project co-led by the University of Kentucky Markey ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Brian Peters started his new role as SVP of the AI Squared division at Apimeds Pharmaceuticals. Pharma market research firm Konovo named Tim Albury as CFO. Tenpoint Therapeutics announced the ...

Voyager struggles with a negative enterprise value, financial risks, and limited catalysts in a competitive Alzheimer's ...

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do ...

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration.

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...